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Abstract:  Lewis  y  (LeY)  antigen  is  a  difucosylated  oligosaccharide  carried  by 
glycoconjugates  on  the  cell  surface.  Overexpression  of  LeY  is  frequently  observed  in 
epithelial-derived  cancers  and  has  been  correlated  to  the  pathological  staging  and 
prognosis. However, the effects of LeY on ovarian cancer are not yet clear. Previously, we 
transfected the ovarian cancer cell line RMG-I with the α1,2-fucosyltransferase gene to 
obtain stable transfectants, RMG-I-H, that highly express LeY. In the present study, we 
examined the proliferation, tumorigenesis, adhesion and invasion of the cell lines with 
treatment of LeY monoclonal antibody (mAb). Additionally, we examined the expression 
of  TGF-β1,  VEGF  and  b-FGF  in  xenograft  tumors.  The  results  showed  that  the 
proliferation and adhesion in vitro were significantly inhibited by treatment of RMG-I-H 
cells  with  LeY  mAb.  When  subcutaneously  inoculated  in  nude  mice,  RMG-I-H  cells 
produced  large  tumors,  while  mock-transfected  cells  RMG-I-C  and  the  parental  cells 
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RMG-I produced small tumors. Moreover, the tumor formation by RMG-I-H cells was 
inhibited by preincubating the cells with LeY mAb. Notably, the expression of TGF-β1, 
VEGF and b-FGF all increased in RMG-I-H cells. In conclusion, LeY plays an important 
role in promoting cell proliferation, tumorigenecity and adhesion, and these effects may be 
related to increased levels of growth factors. The LeY antibody shows potential application 
in the treatment of LeY-positive tumors. 
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1. Introduction 
Ovarian cancer is the most lethal gynecologic malignancy. Ovarian cancer at its early stages is 
difficult to diagnose until it spreads and advances to later stages.  Invasion and metastasis are the 
leading  cause  for  poor  prognosis  and  death.  Studies  have  found  that  glycoconjugates  on  the  cell 
membrane  are  closely  related  to  cellular  biological  characteristics  such  as  cell  adhesion,  invasion  
and metastasis [1–3]. Lewis y (LeY) is a difucosylated oligosaccharide with the chemical structure 
[Fucα1→2Galβ1→4(Fucα1→3)GlcNAcβ1→R], belonging to A, B, H, Lewis blood group antigens 
family.  Under  normal  physiological  conditions,  LeY  is  mainly  expressed  during  embryonic 
development. In adults, its expression is confined to the epithelium and granulocytes [4]. However, 
LeY antigen is expressed in most epithelial-derived cancer cells, among which 70–90% shows an 
increased expression of LeY antigen, including colon, stomach, ovary, breast and lung cancer [5–9]. In 
breast  and  lung  cancer  patients,  the  expression  of  LeY  antigen  correlates  positively  with  poor 
prognosis [8,9]. 
α1,2-fucosyltransferase (α1,2-FT) is the key enzyme in LeY synthesis. Previously, we transfected 
the ovarian cancer cell line RMG-I with human α1,2-FT gene (FUT1) to obtain stable transfectants, 
RMG-I-H, that highly express LeY [10,11]. Our studies showed that, compared with cells without 
transfection, RMG-I-H cells have enhanced malignant behavior, a shorter cell cycle, and increased 
resistance  to  5-fluorouracil.  [10,12]  suggesting  that  LeY  is  involved  in  the  changes  in  biological 
behavior of the RMG-I-H cells. 
LeY is a potential therapeutic target for LeY-positive cancers. Anti-LeY mAb have been shown to 
have  excellent  specificity  and  potential  therapeutic  value  in  the  treatment  of  prostate  [13],  
breast [14,15] and small cell lung cancer [16]. However, there is no such evidence showing their 
effects on ovarian cancer. In the present study, we compared the changes in biological behavior of 
RMG-I-H cells after LeY mAb treatment in order to demonstrate the function of LeY antigen and to 
provide a theoretical basis for the biological treatment of ovarian cancer. In addition, we examined the 
expression  of  TGF-β1,  VEGF  and  b-FGF  in  nude  mouse  xenograft  tumors.  We  found  that  the 
expression of all three cytokines was upregulated in RMG-I-H cells. This, on the one hand, provides a 
possible mechanism for the increased proliferation and adhesion in RMG-I-H cells; on the other hand, 
provides a basis for future studies on the role of LeY in signal transduction.  Int. J. Mol. Sci. 2010, 11                
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2. Results 
2.1. Expression of LeY Increases on the Cell Surface after Transfection of the α1, 2-FT Gene 
Previous  results  showed  that  transfection  of  the  α1,  2-FT  gene  into  RMG-I  cells  resulted  in  a  
20–30 fold increase in cellular α1, 2-FT activity [10]. We here verify the expression of LeY on cells. 
Laser confocal microscopy revealed that the expression of LeY on the surface of RMG-I-H cells was 
obviously higher than in RMG-I and RMG-I-C cells (Figure 1A). Immunohistochemical assays were 
performed  to  examine  the  expression  of  LeY  in  nude  mouse  xenograft  tumors  formed  from 
subcutaneous injection with RMG-I, RMG-I-C and RMG-I-H cells. Similarly, the results showed that 
RMG-I-H cells had a higher expression of LeY than the two control groups (P < 0.05) (Figure 1B), 
indicating that the α1, 2-FT gene transfection increased the expression of LeY. 
Figure 1. Determination of expression of LeY. (A) Cells were fixed and stained for LeY 
using  LeY  mAb  labeled  with  Rhodamine  (TRITC)-conjugated  AffiniPure  Goat  
Anti-Mouse IgG (red). Blue: Nuclei stained with 4,6-diamidino-2-phenylindole (DAPI);  
(B) Immunohistochemistry for LeY in xenograft tumors. 
 
2.2. LeY Enhances Proliferation of RMG-I Cells 
Since  proliferation  effectively  reflects  the  malignancy  of  tumors,  studying  proliferation  is  an 
important way to understand the biological behavior of tumors. Using the MTT method, we detected 
absorbance values (490 nm) of cells at different time points after treatment with LeY mAb or the 
control  IgM  antibody.  The  results  showed  that  the  proliferation  in  LeY  mAb-treated  groups  all 
decreased  compared  with  that  in  the  control  IgM  antibody-treated  groups,  among  which  the  LeY  
mAb-treated RMG-I-H cells had the most obvious change (P < 0.05) (Figure 2). The inhibition rates of 
proliferation from day 1 through day 7 were 3.13%, 5.59%, 19.71%, 45.73%, 57.80%, 48.92% and Int. J. Mol. Sci. 2010, 11                
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33.38%, respectively. The highest inhibition rate was on day 5, which was close to 60%. These results 
indicate that elevated expression of LeY led to an increase in the number of RMG-I cells when they 
were cultured in vitro.  
Figure 2. Cell proliferation was determined by the MTT assay. Cells treated with either 
anti-LeY mAb or control IgM antibody were incubated with MTT to perform cell growth 
analysis. Data are means ± SE from three individual experiments. 
 
2.3. LeY Enhances Tumorigenicity of RMG-I Cells 
This experiment was performed to determine the tumorigenic ability of the cell lines in nude mice. 
The results showed that the latent period of tumor growth was 8.8 ± 1.3 d and 8.6 ± 0.5 d in RMG-I 
cells and RMG-I-C cells, respectively, with no significant difference (P > 0.05), whereas the latent 
period of tumor growth was 5.2 ± 0.8 d in RMG-I-H cells, significantly less than that in the control 
groups  (P < 0.01).  The  xenograft  tumor  volume  was  significantly  larger  in  the  RMG-I-H  group 
compared to the control groups (P < 0.01) (Figure 3A). Similarly, tumor weight in the RMG-I-H group 
(2038.8 ± 241.9 mg) was also significantly higher than in the control RMG-I (696.8 ± 73.3 mg) and 
RMG-I-C (707.2 ± 21.8 mg) groups (P < 0.01) (Figure 3B). However, we found no difference between 
the  RMG-I  cells  and  RMG-I-C  cells  in  growth  potential  in  vivo.  To  further  determine  if  tumor 
formation by RMG-I-H is dependent on LeY antigen, cells were inoculated after preincubation with 
LeY mAb. The results shown in Figures 3 (Figures 3C and 3D) illustrate that tumor formation was 
significantly  inhibited  by  LeY  mAb.  These  results  demonstrate  that  LeY  antigen  enhances  the 
tumorigenicity of RMG-I cells in vivo. 
2.4. LeY Enhances Adhesion of RMG-I Cells 
This  experiment  was  performed  to  compare  the  adhesion  of  cells  with  or  without  LeY  mAb 
treatment.  Inverted microscopy revealed that cells in LeY mAb treated  groups failed to spread  or 
spread more slowly, with shorter and smaller cell bases according to morphological analysis. After the 
same culture time, the number of adhered cells in LeY mAb-treated RMG-I-H groups was decreased 
obviously compared with that in the control IgM antibody-treated groups (P < 0.05) (Figure 4), and the 
inhibition rates of adhesion were 53.17%, 61.50% and 50.93% at 10, 30 and 60 min, respectively. The 
results indicate that the LeY antigen is involved in the adhesion of ovarian cancer RMG-I cells. Int. J. Mol. Sci. 2010, 11                
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Figure 3. LeY increases tumor growth in nude mice. 15 nude mice divided into 3 groups 
were injected with RMG-I, RMG-I-C or RMG-I-H  cells [10
7 cells/0.3 mL]. During the 
inhibition  assay,  LeY  mAb  and  irrelevant  IgM  antibody  treated  RMG-I-H  cells 
[10
7 cells/0.3 mL] were subcutaneously injected into nude mice. Tumor volume (A, B) and 
tumor mass (C, D) were assessed as mentioned in the Materials and Methods section. 
 
Figure 4. Changes in cell adhesion after anti-LeY mAb/irrelevant IgM antibody treatment. 
Data are means ± SE from three individual experiments. 
 
2.5. LeY Does Not Affect Cell Invasion of RMG-I Cells 
RMG-I, RMG-I-C and RMG-I-H cells treated with different concentrations of LeY mAb (1 µg/mL, 
5 µg/mL, 10 µg/mL and 20 µg/mL) were subjected to invasion assays using a transwell cell culture 
system. Matrigel were coated on the upper face of the transwell. The results suggested that there was Int. J. Mol. Sci. 2010, 11                
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no detectable difference in invasion between LeY mAb treated groups and control antibody treated 
groups (P > 0.05).  
2.6. LeY Upregulates the Expression of TGF-β1, VEGF and b-FGF 
VEGF,  b-FGF  and  TGF-β1  are  growth  factors  with  multiple  biological  functions  that  play 
important roles in enhancing tumor cell proliferation, angiogenesis and tumor development [17–19]. 
To gain insight into the mechanism for enhanced proliferation, tumorigenicity and adhesion by LeY 
antigen, we examined the expression of TGF-β1, VEGF and b-FGF in both nude mouse xenograft 
tumors  and  cells  cultured  in  vitro  by  immunohistochemical  staining  and  Western  blot  analysis, 
respectively. The results showed that the expression of TGF-β1, VEGF and b-FGF were all increased 
in RMG-I-H cells (P < 0.05) (Figure 5A and 5B), suggesting that the LeY is likely to enhance tumor 
cell proliferation and adhesion by promoting the secretion of these cell growth factors. 
Figure 5. Determination of the expression of TGF-β1, VEGF and b-FGF. (A) Expression 
of  TGF-β1,  VEGF  and  b-FGF  in  nude  mouse  xenograft  tumor  tissues  using 
immunohistochemical  methods;  (B)  Expression  of  TGF-β1,  VEGF  and  b-FGF  in  cells 
cultured in vitro using western blot analysis. 
   
3. Discussion 
Based on previous studies, we treated cells before and after transfection with LeY mAb in order to 
block  the  function  of  LeY  antigen  on  the  cell  surface.  In  vitro  proliferation  and  adhesion  assays 
showed that the LeY mAb significantly inhibited the proliferation and adhesion of RMG-I-H cells. 
More importantly, we tested cell growth in vivo by inoculating subcutaneously the cells into nude mice. 
While the RMG-I cells and RMG-I-C cells with low level of  LeY expression on the cell surface 
produced  small  tumors,  LeY  high-expressing  cells,  RMG-I-H,  grew  large  tumors.  LeY-dependent 
growth of RMG-I-H cells in vivo was supported by the following results: The size and weight of 
tumors derived from RMG-I-H cells were reduced significantly by preincubation of RMG-I-H cells 
with  anti-LeY  mAb.  We  preliminary  found  that  the  lactose  type  I  chain  family  of  the  original  
RMG-I cells were Lc4Cer, Lewis a, and Lewis b, whereas, H-1 instead had the absolute domination in  Int. J. Mol. Sci. 2010, 11                
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RMG-I-H  cells.  For  the  glycolipids  of  the  lactose  type  II  chain  family,  such  as  LeX,  LeY,  
IV3NeuAc-nLc4Cer and NeuAc-LeX, their concentrations were over 0.01 µg per milliliter of dry cells; 
however, the glycolipids shown in RMG-I-H cells were LeX and LeY. 42.6% of LeX in the RMG-I-H 
was converted into LeY, which was in much higher percentage than the 3.2% of the original RMG-I 
cells. Although type I chain family H-1 had the absolute domination in the transfected RMG-I-H cells, 
its actual content was only a quarter of the LeY [10]. These results further proved that the changes in 
biological behavior of RMG-I-H cells had to do with the increase in LeY antigen. All these results 
indicate that the LeY antigen is related to increased cell proliferation, adhesion and tumorigenecity of 
RMG-I-H cells.  
LeY  causes  significant  enhancement  of  proliferation  and  growth  possibly  due  to  the  following 
reasons. First, LeY structure was found being contained within the epidermal growth factor receptor 
(EGFR) on the surface of tumor cells and to participate in EGFR signaling [20–22]. Second, LeY 
antigen is likely an effective mediator to promote angiogenesis. VEGF and b-FGF are two powerful 
angiogenic cytokines. Zhu et al. [23] studied the role of LeY/H antigen in angiogenesis via in vitro 
experiments using a sugar analog (H-2g) of the LeY-6/H-5-2 (LeY/H) antigen. The results showed that 
H-2g activated NFκB through the JAK2 and the PI3K pathways, which induced the expression of 
VEGF and bFGF, thereby mediating angiogenesis. Previously, we used gene chip techniques to detect 
the differential expression of tumor-related genes after α1, 2-FT gene transfection [24]. The results 
showed 88 differentially expressed genes after transfection, among which VEGFB gene expression 
was  up-regulated.  In  the  present  study,  we  demonstrated  that  the  expression  of  VEGF  and  bFGF 
increased in ovarian cancer RMG-I-H cells, providing further evidence that there are important links 
between the LeY antigen and angiogenesis. Furthermore, our recent study showed that the TGF-β 
receptors also contain the structure of LeY. The amount of LeY in the structure of TGF-β receptors 
was significantly increased in RMG-I-H cells, and the TGF-β-dependent activation of the MAPK and 
the PI3K signaling pathways was enhanced (unpublished work [25]). 
Zhang et al. [26] studied the association between surface glycan structure and biological behaviors 
of human hepatoma cell line 7721 using a-L-fucosidase to remove terminal fucosyl residues on the cell 
surface. Their results suggested that fucose is involved in adhesion.
 LeY is mainly distributed at the 
plasma  membrane  of  cancer  cells,  and  carried  by  different  glycolipids  and  glycoproteins.  Studies 
showed  that  changes  in  fucosyltransferase  expression  might  affect  LeY  structure  on  cell  surface 
receptors  and  therefore  impact  the  expression  and  function  of  some  adhesion-related  glycoprotein 
receptors, such as CD44v6 [27], ICAM-2 [28] and integrins [29]. In the present study we demonstrate 
by in vitro adhesion assay that LeY mAb can efficiently inhibit the adhesive ability of RMG-I-H cells, 
further demonstrated that LeY is involved in adhesion of RMG-I cells. In addition, we used matrigel to 
establish  an  artificial  basement  membrane  and  determined  their  invasive  potential  by  testing  the 
number of tumor cells able to penetrate the membrane. The results showed that the effect of LeY on 
the invasion of ovarian cancer cells was not significant. However, the results may be related to the 
antibody used, so further experiments are required. Int. J. Mol. Sci. 2010, 11                
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4. Materials and Methods 
4.1. Reagents and Cell Lines 
Mouse  anti-human  LeY  mAb  (clone  A70-C/C8)  [30]  was  purchased  from  Abcam  (England). 
Rhodamine  (TRITC)-conjugated  AffiniPure  goat  anti-mouse  IgG  (H+L)  was  purchased  from 
Zhongshan  Biotechnology  (China).  Mouse  anti-human  IgM  antibody,  MTT  reagents  and  
4,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma (U.S.). The transwell (two vertical 
chambers separated by an 8 µm layer of polycarbonate membrane) was purchased from Corning (US). 
Matrigel was from BD Biosciences (US). Rabbit anti-human VEGF, rabbit anti-human b-FGF and 
rabbit anti-human TGF-β1 polyclonal antibodies were from Santa Cruz (US). The immunohistochemical 
SABC kit was purchased from Boster Biological Technology, Inc. (Wuhan, China). 
The RMG-I cell line, which was originated from ovarian clear cell carcinoma, donated by Professor 
Iwamori Masao of Tokyo University of Japan. RMG-I-H is the cell line with a high expression of 
α1,2-FT and LeY antigen, and was established as previously reported [10,11]. RMG-I-C was the cell 
line  transfected  with  the  vector  alone.  The  cells  were  cultured  in  DMEM  (high-glucose)  media 
(Invitrogen, Carlsbad, CA) containing 10% FBS (Clark, Australia) at 37 °C in a 5% CO2 incubator.  
4.2. Laser Confocal Microscopy  
The cells were seeded on a slide and fixed with 4% paraformaldehyde. The mouse anti-human  
LeY  mAb  was  diluted  at  1:100  as  the  working  primary  antibody;  the  goat  anti-mouse  TRITC 
fluorescence-conjugated secondary antibody was diluted at 1:200 as the working secondary antibody. 
After blocking with normal goat serum for 30 min, the cells were incubated with the working primary 
antibody at 37 °C for 1 h and then left at 4 °C overnight. After washing with PBS, the cells were 
incubated with the working secondary antibody at 37 °C for 100 min. DAPI was then used to stain the 
nuclei at room temperature for 5 min. The stained slide was observed under a laser confocal microscope 
(C1-SI; Nikon, Tokyo, Japan). Data were collected with a computer to generate digital images.  
4.3. Cell Proliferation Assay 
The cells were seeded in a 96-well plate at 2 × 10
4 cells/well (three replicates), incubated at room 
temperature for 2 h, and then cultured in DMEM (with 10% FCS) containing LeY mAb (10 µg/mL) as 
previously described [31]. Mouse anti-human IgM antibody was added as control. Cells were cultured 
in 5% CO2 at 37 °C for 72 h, and then 20 µL of 5 mg/mL MTT was added. After 5 h of subsequent 
culture, 150 µL of DMSO was added to terminate the reaction, and the absorbance value was detected 
at 490 nm using a microplate reader (Elx808; Bio-Tek Instruments, Vermont, USA).  
4.4. Subcutaneous Xenograft Tumor Model in Nude Mice  
Ethical approval was obtained from China Medical University animal ethics committee before the 
start of the study. Fifteen 5–6 week old healthy female nude mice (Balb/c nu/nu, purchased from 
Liaoning  Experimental  Animal  Center)  were  randomized  into  three  groups  and  given  a  dorsal 
subcutaneous injection with RMG-I, RMG-I-C or RMG-I-H single cell suspensions (10
7 cells/0.3 mL). Int. J. Mol. Sci. 2010, 11                
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In  the  inhibition  experiments,  10
7  cells  were  first  preincubated  with  LeY  mAb  or  IgM  antibody 
(10 µg/mL) as previously described [31]. Cells were then washed with PBS and resuspended in 0.3 mL 
of serum-free DMEM media. These cells were incubated subcutaneously as described above. Animals 
were raised under SPF conditions and their general status was periodically monitored. The length (a), 
width (b) and height (c) of the tumors were measured by Vernier caliper, and the approximate tumor 
volume (V) was calculated by the formula V = π/6(abc). For small tumors, the height (depth) was 
roughly equal to the smaller value between a and b. The nude mice were all sacrificed 50 days later, 
and the tumors were isolated and weighed. The tumor tissues were then fixed in 10% formaldehyde, 
embedded in paraffin and cut into sequential slices (4 µm). 
4.5. Cell Adhesion Assay 
LeY  mAb  (10  µg/mL)  and  the  control  IgM  antibody  were  added  to  single-cell  suspensions, 
respectively. The cells were incubated at 37 °C for 30 min and then seeded into Petri dishes (35 mm) 
at 3 × 10
5 cells/dish. Three dishes were randomly placed into each group after 10, 30, and 60 min of 
culture, and were then washed with PBS to remove non-adherent cells. Adherent cells were digested 
off and counted. The inhibition rate (IR) was calculated by the following formula: 
IR = [1 − (adherent cells in experimental groups/adherent cells in control groups)] × 100% 
4.6. Cell Invasion Assay 
The bottom of the upper chamber was covered with a layer of matrigel to form a bottom barrier and 
dried overnight. 600 µL of 20% cell culture medium was added to the lower chamber, and 100 µL of cell 
suspension (1 × 10
6/mL) was added to the upper chamber. After 2 h of incubation in 5% CO2 at 37 °C, 
LeY mAb was added to both the upper and the lower chambers (at a final concentration of 1, 5, 10 or  
20 µg/mL). Cells that did not migrate through the membrane were removed, and the cells that migrated 
to the lower face of the membrane were fixed with methanol followed by staining with Giemsa. The 
numbers of cells on the lower face were counted using a high-power field under microscope. There were 
three replicates at each concentration from each group, and the experiment was repeated three times.  
4.7. Immunohistochemical Staining  
The tissue sections were processed by the general deparaffinization and hydration procedure, and 
were then soaked in freshly prepared 3% hydrogen peroxide for 10 min. After antigen retrieval, the 
tissue sections were incubated in normal goat serum for 30 min. Primary antibodies (1:100) were then 
added and incubated at 4 °C overnight. Biotin-conjugated secondary antibodies were added, followed 
by 20 min incubation at 37 °C. The SABC reagent was then added, followed by 30 min incubation at 
37 °C. The sections were developed by DAB and monitored under the microscope. After counterstaining 
with hematoxylin, the slides were dehydrated, cleared, mounted, and observed under a microscope. 
4.8. Western Blot Analysis  
Cells were rinsed with PBS, and 1% of Triton X-100 lysis buffer (20 mM Tris-HCl, pH 7.4, 10 mM 
EGTA, 10 mM MgCl2, 1 mM benzamidine, 60 mM β-glycerophosphate, 1 mM Na3VO4, 20 mM NaF, Int. J. Mol. Sci. 2010, 11                
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2  µg/mL  aprotinin,  5  µg/mL  leupeptin,  0.1  mM  phenylmethylsulfonyl  fluoride)  was  added.  The 
suspension was centrifuged, and the supernatants were collected. Protein content was measured using 
the protein assay BCA kit (Beyotime biotechnology, China), and equal amounts of protein were loaded 
on SDS-PAGE gels. Subsequently, proteins were transferred to PVDF membranes (Millipore, Beaford, 
MA)  and  were  probed  with  antibodies  (1:1000).  Immunoreactive  bands  were  visualized  by 
chemiluminescence (ECL; Pierce) using a secondary antibodies (1:8000).  
4.9. Statistical Analysis 
The SPSS 12.0 statistical analysis software was used, and the analysis of One-Way ANOVA was 
employed. P < 0.05 was regarded as with statistical significance. 
5. Conclusions 
Our study demonstrates that LeY antigen plays an important role in promoting the development of 
ovarian  cancer,  and  that  the  LeY  antigen  may  affect  the  behavior  of  ovarian  cancer  cells  by 
upregulating the secretion of TGF-β1, VEGF and b-FGF.  
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